[Edaily Reporter KYUNG GYEYOUNG ] Hyungji Global returned to profitability in the second quarter as it focused on revenue growth this year.
Castelbajac Co., Ltd.(308100)The company announced on the 14th that its consolidated operating profit for the second quarter was 264.5 million won, marking a return to profitability compared to the second quarter of last year. Revenue for the same period rose 130.7% to 23.3 billion won.
On a standalone basis, revenue and operating profit were 11.3 billion won and 500 million won, respectively. These figures represent a 31.4% increase compared to the second quarter of last year and mark a return to profitability.
In this regard, Hyungji Global viewed this as a sign that it not only expanded its scale by integrating the Hyungji Esquia business but also solidified the growth foundation of its existing businesses. Profitability improved as Castelbajac strengthened its quality competitiveness while diversifying its sales channels to include overseas buyers, outlets, and local distributors, and bolstered online and home shopping channels.
An official from Hyungji Global stated, “While last year we focused on improving profitability and securing financial stability through management centered on solid fundamentals, this year we have concentrated our efforts on expanding our business scale, including the reorganization of sales channels.” The official added, “Since we have simultaneously achieved sales growth, improved profitability, and normalized our financial structure, we will continue to sustain this turnaround momentum in the second half of the year.”
Consolidated basis; unit: 100 million won; source: Hyungji Global
KBI METAL CO., LTD.’s Eumseong Plant Office Building. (Photo courtesy of KBI Group)
KBI METAL CO., LTD. posted its highest-ever cumulative operating profit for the first three quarters of this year,…
“Please continue to look favorably upon our Shenyang Oak Soju.”This is a handwritten message posted by Cho Woong-rae, Chairman of Seonyang Soju, on his Instagram on the 12th. In his handwritten messag…
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…